Gastrointestinal tolerability of meloxicam and piroxicam: A double-blind placebo-controlled study

British Journal of Clinical Pharmacology

Volumn 46, Issue 2, 1998, Pages 133-137

  Lipscomb, G R ^b   Wallis, N ^a   Armstrong, G ^c   Rees, W D W ^a  

^a Salford Royal Hospital   (United Kingdom)

^b NORTH MANCHESTER GENERAL HOSPITAL   (United Kingdom)

^c NONE

Author keywords

Adaptation; Meloxicam; Mucosal blood flow; Non steroidal anti inflammatory drugs; Piroxicam

Indexed keywords

MELOXICAM; NONSTEROID ANTIINFLAMMATORY AGENT; PIROXICAM; PLACEBO; PROSTAGLANDIN E2;

ADULT; ALCOHOL CONSUMPTION; ARTICLE; BIOPSY; BLOOD FLOW; CLINICAL TRIAL; CONTROLLED STUDY; DUODENUM MUCOSA; DYSPEPSIA; ENDOSCOPY; FEMALE; GASTROINTESTINAL MUCOSA; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN EXPERIMENT; HUMAN TISSUE; MALE; NAUSEA; NORMAL HUMAN; ORAL DRUG ADMINISTRATION; PRIORITY JOURNAL; PROSTAGLANDIN SYNTHESIS; RASH; SMOKING; STOMACH INJURY;

ADULT; ANTI-INFLAMMATORY AGENTS, NON-STEROIDAL; CYCLOOXYGENASE INHIBITORS; DINOPROSTONE; DOUBLE-BLIND METHOD; DUODENUM; ENDOSCOPY, GASTROINTESTINAL; FEMALE; GASTRIC MUCOSA; HUMANS; INTESTINAL MUCOSA; MALE; PIROXICAM; THIAZINES; THIAZOLES; TIME FACTORS;

EID: 0031859367     PISSN: 03065251     EISSN: None     Source Type: Journal    
DOI: 10.1046/j.1365-2125.1998.00761.x     Document Type: Article

References (20)

1. Henry D, Dobson A, Turner C. Variability in the risk of major gastrointestinal complications from non-aspirin, non-steroidal anti-inflammatory drugs. Gastroenterology 1993; 103: 1078-1088.
2. Vane JR. Inhibition of prostaglandin synthesis as a mechanism of action for aspirin like drugs. Nature New Biol 1971; 231: 232.
3. Lipscomb GR, Rees WDW. Gastric mucosal injury and adaptation to oral and rectal administration of naproxen. Aliment Pharmacol Ther 1996; 10: 133-139.
4. 2 metabolism. Gut 1991; 33: 164-169.
5. Konturek JW, Dembinski A, Stoll R, Domschke W, Konturek SJ, Mucosal adaptation to aspirin induced gastric damage in humans. Studies on blood flow and gastric mucosal growth and neutrophil activation. Gut 1994; 35: 1197-1204.
6. Litchenberger LM, Wang Z, Romero JJ, et al. Non-steroidal anti-inflammatory drugs (NSAIDs) associate with zwitterionic phospholipids: Insight into the mechanism and reversal of NSAID-induced gastrointestinal injury. Nature Med 1995; 1: 154-158.
7. Elliot SN, McKnight W, Cirino G, Wallace JL. A nitric oxide-releasing non-steroidal anti-inflammatory drug accelerates gastric ulcer healing in rats. Gastroenterology 1995; 109: 524-530.
8. Xie W, Chipman JG, Robertson DL, Erikson RL, Simmons DL. Expression of mitogen-responsive gene encoding prostaglandin synthase is regulated by mRNA splicing. Proc Natl Acad Sci USA; 88: 2692-2696.
9. Linden B, Distel M, Bluhmki E. A double blind study to compare the efficacy and safety of meloxicam 15 mg with piroxicam 20 mg in patients with osteoarthritis of the hip. Br J Rheumatol 1996; 35: 35-38.
10. Huskisson EC. Efficacy and tolerance of meloxicam, a new NSAID in daily oral doses of 15,30 and 60 mg in comparison to 20 mg piroxicam in patients with rheumatoid arthritis. Scand J Rheumatol 1994; (suppl 98): 115.
11. Lipscomb GR, Wallis N, Armstrong G, Goodman MJ. Rees WDW. Gastric mucosal adaptation to etodolac and naproxen. Aliment Pharmacol Ther 1995; 9: 379-385.
12. Patoia L, Santucci L, Furno P, et al. A 4 week, double-blind, parallel-group study to compare the gastrointestinal effects of meloxicam 7.5 mg, meloxicam 15 mg, piroxicam 20 mg and placebo by means of faecal blood loss, endoscopy and symptom evaluation in healthy volunteers. Br J Rheumatol 1996; 35: 61-67.
13. Graham DY, Lacey Smith J, Dobbs SM. Gastric adaptation occurs with aspirin administration in man. Dig Dis Sci 1983: 28: 1-6.
14. Hawkey CJ, Rampton DS. Prostaglandins and the gastrointestinal mucosa: are they important in its function, disease, or treatment? Gastroenterology 1985; 89: 116-288.
15. Engelhardt G. Pharmacology of meloxicam, a new non-steroidal anti-inflammatory drug with an improved safety profile through preferential inhibition of COX-2. Br J Rheumatol 1996; 35: 4-12.
16. Allen PIM, Wheatley K, Goldman M. Human gastric perfusion: evidence for non-uniformity of blood flow. Br J Surg 1988; 75: 741-747.
17. Gabriel SE, Jaakimainnen L, Bombardier C. Risk for serious gastrointestinal complications related to use of non-steroidal anti-inflammatory drugs. A meta-analysis. Ann Intern Med 1991; 115: 787-796.
18. Henry DA, Lim LL, Garcia Rodriguez ??, et al. Variability in the risk of gastrointestinal complications with individual non-steroidal anti-inflammatory drugs: results of a collaberative meta-analysis. Br Med J 1996; 312: 1563-1566.
19. Skeljo MV, Giraud A, Yeomans MD. Adaptation of rat gastric mucosa to repeated doses of non-salicylate non-steroidal anti-inflammatory drugs. J Gastroenterol Hepatol 1992; 7: 586-590.
20. Distel M, Mueller C, Bluhmki E, Fries J. Safety of meloxicam: a global analysis of clinical trials. Br J Rheumatol 1996; 35: 68-77.